The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Advances and challenges in the treatment of esophageal cancer
Open accessAbstract
Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dong, H., Hu, J., Zou, K., Ye, M., Chen, Y., Wu, C., Chen, X., & Han, M. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0931-9 · Cited by 247
RetractedKang, M., Ren, M., Li, Y., Fu, Y., Deng, M., & Li, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0845-9 · Cited by 180
RetractedYang, C., Zheng, X., Ye, K., Sun, Y., Lu, Y., Fan, Q., & Ge, H. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.037 · Cited by 13
RetractedPennathur, A., Gibson, M. K., Jobe, B. A., & Luketich, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60643-6 · Cited by 2,390
Rustgi, A. K., & El-Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,243
Chen, Y., Wang, D., Peng, H., Chen, X., Han, X., Yu, J., Wang, W., Liang, L., Liu, Z., Zheng, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0930-x · Cited by 439
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, L., Kong, P., Wang, J., Li, Y., Chen, W., Song, B., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.017 · Cited by 329
Doi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J., Koshiji, M., & Bennouna, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9846 · Cited by 318
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
Hanawa, M., Suzuki, S., Dobashi, Y., Yamane, T., Kono, K., Enomoto, N., & Ooi, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21454 · Cited by 298
Ciardiello, F., & Tortora, G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00235-1 · Cited by 245
Pedersen, M. W., Jacobsen, H. J., Koefoed, K., Hey, A., Pyke, C., Haurum, J. S., & Kragh, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1417 · Cited by 219
Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 196
Talavera, A., Friemann, R., Gómez-Puerta, S., Martinez-Fleites, C., Garrido, G., Rabasa, A., López-Requena, A., Pupo, A., Johansen, R. F., Sánchez, O., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4518 · Cited by 195
Risk Factors in the Development of Esophageal Adenocarcinoma
Pohl, H., Wrobel, K., Bojarski, C., Voderholzer, W., Sonnenberg, A., Rösch, T., & Baumgart, D. C. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.387 · Cited by 188
Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 174
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
The biological properties of cetuximab
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.006 · Cited by 164
Sánchez-Vega, F., Hechtman, J. F., Castel, P., Ku, G. Y., Tuvy, Y., Won, H. H., Fong, C. J., Bouvier, N., Nanjangud, G. J., Soong, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0598 · Cited by 161
Esophageal carcinoma: Towards targeted therapies
Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00488-2 · Cited by 158
Zhu, H., Zhang, H., Jin, F., Fang, M., Huang, M., Yang, C. S., Chen, T., Fu, L., & Pan, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1903 · Cited by 158
Che, Y., Wang, J., Li, Y., Lu, Z., Huang, J., Sun, S., Mao, S., Lei, Y., Zang, R., Sun, N., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0808-2 · Cited by 151
Kono, K., Iinuma, H., Akutsu, Y., Tanaka, H., Hayashi, N., Uchikado, Y., Noguchi, T., Fujii, H., Okinaka, K., Fukushima, R., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-141 · Cited by 141
Kono, K., Mizukami, Y., Daigo, Y., Takano, A., Masuda, K., Yoshida, K., Tsunoda, T., Kawaguchi, Y., Nakamura, Y., & Fujii, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01200.x · Cited by 137
Antony, J., Tan, T. Z., Kelly, Z., Low, J. J. H., Choolani, M. A., Recchi, C., Gabra, H., Thiery, J. P., & Huang, R. Y. (2016) · Science Signaling · doi:10.1126/scisignal.aaf8175 · Cited by 125
Tsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., Oda, Y., Okano, S., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13237 · Cited by 123
Cao, Y., Yu, J., Liu, T., Yang, K.-X., Yang, L.-Y., Chen, Q., Shi, F., Hao, J., Cai, Y., Wang, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0068-6 · Cited by 122
Kageyama, S., Wada, H., Muro, K., Niwa, Y., Ueda, S., Miyata, H., Takiguchi, S., Sugino, S. H., Miyahara, Y., Ikeda, H., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-246 · Cited by 115
Raza, A., Merhi, M., Inchakalody, V. P., Krishnankutty, R., Relecom, A., Shahab Uddin, M. S., & Dermime, S. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02306-y · Cited by 111
Ng, H. Y., Li, J., Tao, L., Lam, A. K.-Y., Chan, K. W., Ko, J. M. Y., Yu, V. Z., Wong, M., Li, B. C., & Lung, M. L. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.005 · Cited by 98
A good start of immunotherapy in esophageal cancer
Zhao, Q., Yu, J., & Meng, X. (2019) · Cancer Medicine · doi:10.1002/cam4.2336 · Cited by 98
Iinuma, H., Fukushima, R., Inaba, T., Tamura, J., Inoue, T., Ogawa, E., Horikawa, M., Ikeda, Y., Matsutani, N., Takeda, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-84 · Cited by 97
Tajaldini, M., Samadi, F., Khosravi, A., Ghasemnejad, A., & Asadi, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109594 · Cited by 95
Zang, W., Wang, T., Wang, Y., Chen, X., Du, Y., Sun, Q., Li, M., Dong, Z., & Zhao, G. (2016) · Oncotarget · doi:10.18632/oncotarget.6963 · Cited by 91
Chen, X., Wang, L., Li, P., Song, M., Qin, G., Gao, Q., Zhang, Z., Yue, D., Wang, D., Nan, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31730 · Cited by 91
Insights Into the Pathophysiology of Esophageal Adenocarcinoma
Quante, M., Graham, T. A., & Jansen, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.046 · Cited by 89
miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression
Wang, Y., Zhao, Y., Herbst, A., Kalinski, T., Qin, J., Wang, X., Jiang, Z., Benedix, F., Franke, S., Wartman, T., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001928 · Cited by 84
Differential role of microRNAs in the pathogenesis and treatment of Esophageal cancer
Hemmatzadeh, M., Mohammadi, H., Karimi, M., Musavishenas, M. H., & Baradaran, B. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.009 · Cited by 80
Chen, P., Zhang, J., Sha, B., Ma, Y.-E., Hu, T., Ma, Y., Sun, H., Shi, J., Dong, Z., & Li, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15832 · Cited by 79
Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis
Zhang, X.-F., Pan, K., Weng, D., Chen, C.-L., Wang, Q.-J., Zhao, J.-J., Pan, Q., Liu, Q., Jiang, S.-S., Li, Y.-Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8476 · Cited by 73
Mimura, K., Kono, K., Maruyama, T., Watanabe, M., Izawa, S., Shiba, S., Mizukami, Y., Kawaguchi, Y., Inoue, M., Kono, T., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25896 · Cited by 69
Immunotherapy for Esophageal Squamous Cell Carcinoma
Kojima, T., & Doi, T. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0590-9 · Cited by 62
Hua, T., Qian, P., Wang, F., Yu, H., & Guo, Y. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14900505020895 · Cited by 62
STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma
Zhang, Q., Zhang, C., He, J., Guo, Q., Hu, D., Yang, X., Wang, J., Kang, Y., She, R., Wang, Z., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2823-y · Cited by 61
Li, B., Hong, P., Zheng, C., Dai, W., Chen, W., Yang, Q.-S., Han, L., Tsao, S. W., Chan, K. T., Lee, N. P. Y., et al. (2019) · Theranostics · doi:10.7150/thno.30372 · Cited by 61
Liu, H., Zhao, J., Fu, R., Zhu, C., & Fan, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216759 · Cited by 60
Morelli, M. P., Cascone, T., Troiani, T., Tuccillo, C., Bianco, R., Normanno, N., Romano, M., Veneziani, B. M., Fontanini, G., Eckhardt, S. G., et al. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20666 · Cited by 58
Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
Zhang, Y., Zhang, Y., & Zhang, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02840-3 · Cited by 56
Bando, H., Kotani, D., Tsushima, T., Hara, H., Kadowaki, S., Kato, K., Chìn, K., Yamaguchi, K., Kageyama, S., Hojo, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06716-5 · Cited by 56
Lin, K., Jiang, H., Zhuang, S.-S., Qin, Y., Qiu, G., She, Y., Zheng, J., Chen, C., Fang, L., & Zhang, S.-Y. (2018) · The FASEB Journal · doi:10.1096/fj.201800759r · Cited by 55
Shi, Q. W., Shen, L., Dong, B., Fu, H., Kang, X., Yang, Y., Dai, L. X., Yan, W., Xiong, H., Liang, Z., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.010 · Cited by 53
Zou, J., Li, S., Chen, Z., Lü, Z., Gao, J., Zou, J., Lin, X., Li, Y., Zhang, C., & Shen, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0700-0 · Cited by 51
Zhang, Y.-T. Y., Zhu, X., Huang, T., Chen, L., Liu, Y., Li, Q., Song, J., Ma, S., Zhang, K., Yang, B., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.08.010 · Cited by 50
Shi, H. M., Yu, F., Mao, Y., Ju, Q., Wu, Y. C., Wen, B., Wang, P., Xu, R., Jiang, M., & Shi, J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.91 · Cited by 46
Wu, X.-H., Zhang, J., Zhen, R., Lv, J., Li, Z., Su, X., Zhu, G., Gavine, P. R., Xu, L., Lu, S., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-180 · Cited by 45
Cui, C., Chang, Y., Zhang, X., Choi, S., Tran, H., Penmetsa, K. V., Viswanadha, S., Fu, L., & Pan, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.006 · Cited by 45
Hong, J., Katsha, A. M., Lu, P., Shyr, Y., Belkhiri, A., & El-Rifai, W. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1119 · Cited by 44
Cai, R., Wang, P., Zhao, X., Lu, X., Deng, R., Wang, X., Su, Z., Hong, C., & Lin, J. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02310-2 · Cited by 44
VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression
Liu, P., Zhou, J., Zhu, H. Y., Xie, L., Wang, F., Liu, B., Shen, W., Wu, Y., Xiang, B., Zhu, X., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.008 · Cited by 43
Fujihara, S., Morishita, A., Ogawa, K., Tadokoro, T., Chiyo, T., Kato, K., Kobara, H., Mori, H., Iwama, H., & Masaki, T. (2016) · Oncotarget · doi:10.18632/oncotarget.14345 · Cited by 43
Chen, Q., Song, S., Wei, S., Liu, B., Honjo, S., Scott, A. W., Jin, J., Ma, L., Zhu, H., Skinner, H. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4540 · Cited by 42
Hong, D., Liu, T., Huang, W., Liao, Y., Wang, L., Zhang, Z., Chen, H., Zhang, X., & Xiang, Q. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491060 · Cited by 42
PD-1 Inhibitors in the Advanced Esophageal Cancer
Hong, Y., & Ding, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01418 · Cited by 42
C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.
Liang, M., Yu, F., & Chen, C. (2020) · PubMed Central · Cited by 42
Tang, J., An, R., Jiang, Y., & Yang, J. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.485 · Cited by 41
Zhang, W., Pang, Q., Yan, C., Wang, Q., Yang, J., Yu, S., Liu, X., Yuan, Z., Wang, P., & Xiao, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s118982 · Cited by 41
Self-citationLiu, Z., Chen, Z., Wang, J., Zhang, M., Li, Z., Wang, S., Dong, B., Zhang, C., Gao, J., & Shen, L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0651-z · Cited by 40
Lange, T., Nentwich, M. F., Lueth, M., Yekebas, E. F., & Schumacher, U. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.013 · Cited by 39
Zhang, J., Jiang, D., Li, X., Lv, J., Xie, L., Li, Z., Gavine, P. R., Hu, Q., Shi, Y., Tan, L., et al. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.77 · Cited by 38
Hu, X., Wang, R., Jin, J., Liu, X., Cui, A.-L., Sun, L., Li, Y., Li, Y., Wang, Y., Zhen, Y., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12400 · Cited by 38
Self-citationThe Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review
Moujaess, E., Haddad, F., Eid, R., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2019-0087 · Cited by 36
Nie, C., Qin, X., Li, X., Tian, B., Zhao, Y., Jin, Y., Li, Y., Wang, Q., Zeng, D., Hong, A., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00185 · Cited by 35
Wagener‐Ryczek, S., Schoemmel, M., Kraemer, M., Bruns, C. J., Schroeder, W., Zander, T., Gebauer, F., Alakus, H., Merkelbach‐Bruse, S., Buettner, R., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02475-w · Cited by 35
Yuan, H., Zhou, W., Yang, Y., Xue, L., Liu, L., & Song, Y. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.03.017 · Cited by 34
Promising immunotherapies for esophageal cancer
Tanaka, T., Nakamura, J., & Noshirο, H. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315404 · Cited by 33
Lu, Z., Shi, X., Gong, F., Li, S., Wang, Y., Ren, Y., Zhang, M.-Y., Yu, B., Li, Y., Zhao, W. H., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.010 · Cited by 33
Min, A. K. T., Okayama, H., Saito, M., Ashizawa, M., Aoto, K., Nakajima, T., Saito, K., Hayase, S., Sakamoto, W., Tada, T., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1564 · Cited by 32
Daiko, H., Marafioti, T., Fujiwara, T., Shirakawa, Y., Nakatsura, T., Kato, K., Puccio, I., Hikichi, T., Yoshimura, S., Nakagawa, T., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02619-3 · Cited by 32
Investigation of Tumor Suppressing Function of CACNA2D3 in Esophageal Squamous Cell Carcinoma
Li, Y., Zhu, C.-L., Nie, C., Li, J.-C., Zeng, T.-T., Zhou, J., Chen, J., Chen, K., Fu, L., Liu, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060027 · Cited by 31
Xie, X., Zu, X., Liu, F., Wang, T., Wang, X., Chen, H., Liu, K., Wang, P., Liu, F., Zheng, Y., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23007 · Cited by 31
Wang, C., Pu, J., Yu, H., Liu, Y., Yan, H., He, Z., & Feng, X. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000155 · Cited by 30
Ako, E., Yamashita, Y., Ohira, M., et al. (2007) · Oncology Reports · doi:10.3892/or.17.4.887 · Cited by 28
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions
Samson, P. P., & Lockhart, A. C. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.13 · Cited by 28
Wu, D., Li, J., Hu, X., Ma, J., & Dong, W. (2018) · RSC Advances · doi:10.1039/c8ra00956b · Cited by 28
Yoshioka, M., Ohashi, S., Ida, T., Nakai, Y., Kikuchi, O., Amanuma, Y., Matsubara, J., Yamada, A., Miyamoto, S., Natsuizaka, M., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0572-7 · Cited by 27
Gong, J., Liu, X., Li, Y., & Zhen, Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1827-9 · Cited by 26
Self-citationZhang, C., Ma, Q., Shi, Y., Li, X., Wang, M., Wang, J., Ge, J., Chen, Z., Wang, Z., & Jiang, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5539 · Cited by 26
The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis
Li, H., Jiang, C., Wu, D., Shi, S., Liao, M., Wang, J., Li, Y., & Xu, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180271 · Cited by 26
Nakamura, Y., Togashi, Y., Nakahara, H., Tomida, S., Banno, E., Terashima, M., Hayashi, H., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0737 · Cited by 24
Hassan, S., Awasthi, N., Li, J., Williams, F., Schwarz, M. A., Schwarz, R. E., & von Holzen, U. W. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.022 · Cited by 24
Yang, P., Liu, Y., Chang, Y.-H., Lin, C.-C., Huang, P., Hua, K., Lee, J., & Hsieh, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01138 · Cited by 23
Zhu, H., Wang, C., Wang, J., Chen, D., Deng, J., Deng, J., Fan, J., Badakhshi, H., Huang, X., Zhang, L., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.18 · Cited by 22
Hassan, S., Williams, F., Awasthi, N., Schwarz, M. A., Schwarz, R. E., Li, J., & von Holzen, U. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-54129-7 · Cited by 22
Guo, X., Li, S., Zhu, X., Dou, Q.-H., & Liu, D. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3627-3 · Cited by 19
Zhang, K., Zhang, B., Bai, Y., & Dai, L. (2019) · Journal of Cancer · doi:10.7150/jca.33983 · Cited by 19
Gefitinib single drug in treatment of advanced esophageal cancer
Lü, H., Xu, Y.-J., Xie, Z., Shi, Y., Zhang, M., Pan, J., & Li, Y. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.200760 · Cited by 18
Wang, X., Zhu, Y., Zhu, L., Chen, X., Xu, Y., Zhao, Y., Shao, Y., Feng, L., Jiang, Y., Lü, J., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6390 · Cited by 18
Thrift, A. P. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.03.028 · Cited by 17
Hong, J., Maacha, S., & Belkhiri, A. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12395 · Cited by 17
Targeting the overexpressed CREB inhibits esophageal squamous cell carcinoma cell growth
Chen, P., Li, M., Hao, Q., Zhao, X., & Hu, T. (2017) · Oncology Reports · doi:10.3892/or.2017.6167 · Cited by 16
Doxorubicin‐loaded poly(ε‐caprolactone)‐Pluronic micelle for targeted therapy of esophageal cancer
Dai, S., Ye, Z., Wang, F., Yan, F., Wang, L., Fang, J., Wang, Z., & Fu, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27159 · Cited by 16
Wang, J.-N., Che, Y., Yuan, Z.-Y., Lu, Z.-L., Li, Y., Zhang, Z.-R., Li, N., Li, R.-D., Wan, J., Sun, H., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.005 · Cited by 16
Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Saito, T., Kondo, Y., Yamamoto, Y., Mitani, Y., Vu, T. H. N., Fukuyama, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0918 · Cited by 16
Hou, W., Qin, X., Zhu, X., Fei, M., Liu, P., Liu, L., Moon, H., Zhang, P., Greshock, J. D., Bachman, K. E., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2500 · Cited by 15
Liu, T., Yang, K.-X., Yu, J., Cao, Y., Ren, J.-S., Hao, J., Pan, B.-Q., Ma, S., Yang, L.-Y., Cai, Y., et al. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1663-4 · Cited by 15
Immune checkpoint inhibitors: a new era for esophageal cancer
Zou, L., Yang, X., Li, Y., & Zhu, Z. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1654379 · Cited by 15
Cui, G., Cui, M., Li, Y., Liang, Y., Li, W., Guo, H., & Zhao, S. (2015) · Medical Oncology · doi:10.1007/s12032-015-0570-6 · Cited by 14
Hartmans, E., Linssen, M. D., Sikkens, C., Levens, A., Witjes, M. J. H., van Dam, G. M., & Nagengast, W. B. (2017) · Oncotarget · doi:10.18632/oncotarget.16165 · Cited by 14
Zhang, Y., Pan, T., Zhong, X., & Cheng, C. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14150fp · Cited by 12
Fukuoka, S., Kojima, T., Koga, Y., Yamauchi, M., Komatsu, M., Komatsuzaki, R., Sasaki, H., Yasunaga, M., Matsumura, Y., Doi, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14209 · Cited by 10
Kai, J., Wang, Y., Xiong, F., & Wang, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.43 · Cited by 9
Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro
Li, Q., Yang, L., Han, K., Zhu, L., Zhang, Y.-T. Y., Ma, S., Zhang, K., Yang, B., & Guan, F. (2016) · Oncotarget · doi:10.18632/oncotarget.11369 · Cited by 8
Liu, H., Zhao, J., Yang, Y., Jin, G., Zhang, X., Wang, D., Xie, C. L., Liu, K., Chen, X., Li, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6653 · Cited by 8
Wang, J., Ji, H., Zhu, Q., Yu, X., Du, J., & Jiang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.10160 · Cited by 6
Wang, C., Guo, L., Wang, S., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2867 · Cited by 3
Metadata
- Authors
- He, S., Xu, J., Liu, X., & Zhen, Y.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 11
- Issue
- 11
- Pages
- 3379-3392
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3134145478
- Cited by
- 287
- References
- 115
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.